ABO Incompatible Living Donor Liver Transplantation: A Single Center Experience.
10.4285/jkstn.2018.32.4.84
- Author:
Seung Hoon LEE
1
;
Ho Joong CHOI
;
Young Kyoung YOU
;
Dong Goo KIM
;
Gun Hyung NA
Author Information
1. Department of Surgery, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon, Korea. nagh0214@naver.com
- Publication Type:Original Article
- Keywords:
ABO blood-group system;
B-lymphocytes;
Hemagglutinins;
Liver transplantation;
Survival
- MeSH:
ABO Blood-Group System;
Accidents, Traffic;
B-Lymphocytes;
Hand;
Hemagglutinins;
Humans;
Immunologic Factors;
Liver Transplantation*;
Liver*;
Living Donors*;
Lymphocytes;
Methods;
Mortality;
Plasma Exchange;
Retrospective Studies;
Rituximab;
Tissue Donors
- From:The Journal of the Korean Society for Transplantation
2018;32(4):84-91
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: This study examined the outcomes of ABO incompatible living donor liver transplantation (LDLT). The changes in the immunologic factors that might help predict the long term outcomes were also studied. METHODS: Twenty-three patients, who underwent ABO incompatible LDLT from 2010 to 2015, were reviewed retrospectively. The protocol was the same as for ABO compatible LDLT except for the administration of rituximab and plasma exchange. The clinical outcomes and immunologic factors, such as isoagglutinin titer and cluster of differentiation 20+ (CD20+) lymphocyte levels were reviewed. RESULTS: The center showed a 3-year survival of 64% with no case of antibody-mediated rejection. When transplantation-unrelated mortalities (for example, traffic accidents and myocardial infarction) were removed from statistical analysis, the 3-year survival was 77.8%. Although isoagglutinin titers continued to remain at low levels, the CD20+ lymphocyte levels recovered to the pre-Rituximab levels at postoperative one year. CONCLUSIONS: As donor shortages continue, ABO incompatible liver transplantation is a feasible method to expand the donor pool. On the other hand, caution is still needed until more long-term outcomes are reported. Because CD20+ lymphocytes are recovered with time, more immunologic studies will be needed in the future.
